These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 28524171)

  • 1. Endocrine-disrupting chemicals and fatty liver disease.
    Foulds CE; Treviño LS; York B; Walker CL
    Nat Rev Endocrinol; 2017 Aug; 13(8):445-457. PubMed ID: 28524171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease.
    Treviño LS; Katz TA
    Endocrinology; 2018 Jan; 159(1):20-31. PubMed ID: 29126168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent Endocrine-Disrupting Chemicals and Fatty Liver Disease.
    Deierlein AL; Rock S; Park S
    Curr Environ Health Rep; 2017 Dec; 4(4):439-449. PubMed ID: 28980219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review.
    Cano R; Pérez JL; Dávila LA; Ortega Á; Gómez Y; Valero-Cedeño NJ; Parra H; Manzano A; Véliz Castro TI; Albornoz MPD; Cano G; Rojas-Quintero J; Chacín M; Bermúdez V
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between endocrine-disrupting chemical mixtures and non-alcoholic fatty liver disease with metabolic syndrome as a mediator among adults: A population-based study in Korea.
    Park B; Kim B; Kim CH; Oh HJ; Park B
    Ecotoxicol Environ Saf; 2024 May; 276():116310. PubMed ID: 38614002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    Pan K; Xu J; Xu Y; Wang C; Yu J
    Pharmacol Res; 2024 Jul; 205():107251. PubMed ID: 38862070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine disrupting chemicals: A promoter of non-alcoholic fatty liver disease.
    Chen Y; Wang Y; Cui Z; Liu W; Liu B; Zeng Q; Zhao X; Dou J; Cao J
    Front Public Health; 2023; 11():1154837. PubMed ID: 37033031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
    Lau JKC; Zhang X; Yu J
    Adv Exp Med Biol; 2018; 1061():139-147. PubMed ID: 29956212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Deretzi G; Zavos C; Mantzoros CS
    Curr Mol Med; 2012 Jan; 12(1):68-82. PubMed ID: 22082482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flame Retardants-Mediated Interferon Signaling in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Negi CK; Khan S; Dirven H; Bajard L; Bláha L
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
    Dongiovanni P; Romeo S; Valenti L
    World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perinatal exposure to environmental endocrine disruptor bisphenol A aggravates the onset of non-alcoholic fatty liver disease (NAFLD) in weanling F1 offspring of obese rats.
    Dabeer S; Raisuddin S
    Environ Sci Pollut Res Int; 2023 Jan; 30(2):3146-3165. PubMed ID: 35945320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms.
    Lian CY; Zhai ZZ; Li ZF; Wang L
    Chem Biol Interact; 2020 Oct; 330():109199. PubMed ID: 32805210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.